Table 3.

SLE and healthy control cohort characteristics.

	SLE subjects (n = 20)	Control subjects (n = 21)
Age at draw (mean ± SD years)	45.0 ± 17.8	44.0 ± 16
Male/female	1/19	1/20
Race	60% Caucasian, 20% Asian, 10% African American, 10% Unknown	66.6% Caucasian, 19% Asian, 9.5% African American, 4.7% Pacific Islander
Disease duration (mean ± SD years)	10 ± 9.6
SLEDAI score (mean ± SD)	4.6 ± 3.7
ANA+	100%
Therapy	45% Prednisone (2.5–7 mg/day) 80% Hydroxychloroquine

SLEDAI, Systemic lupus erythematosus disease activity index; ANA, antinuclear antibodies.